Zobrazeno 1 - 10 of 121 pro vyhledávání: '"Philippe, Szapary"'
1
Akademický článek
Society for Immunotherapy of Cancer (SITC) recommendations on intratumoral immunotherapy clinical trials (IICT): from premalignant to metastatic disease
Autor: Bart Neyns, Mark Middleton, Aurélien Marabelle, Ignacio Melero, Ke Liu, Nina Bhardwaj, Tanja D de Gruijl, Jason Chesney, Robert Coffin, Howard Kaufman, Diwakar Davar, Jason J Luke, Georgina V Long, Kevin J Harrington, Sherene Loi, Thierry de Baere, David J Pinato, Matthew Fury, Ciara M Kelly, Joshua D Brody, Robert H Andtbacka, Gregory Goldmacher, Anuradha D Khilnani, Rahul A Sheth, Stephen B Solomon, Philippe Szapary
Publikováno v: Journal for ImmunoTherapy of Cancer, Vol 12, Iss 4 (2024)
Background Intratumorally delivered immunotherapies have the potential to favorably alter the local tumor microenvironment and may stimulate systemic host immunity, offering an alternative or adjunct to other local and systemic treatments. Despite th
Externí odkaz: https://doaj.org/article/c46bb380ab4f4bb8bdb94dd95f2f7c6b
Zobrazit plný text záznamu
2
Complications After Transthoracic Needle Biopsy of Pulmonary Nodules: A Population-Level Retrospective Cohort Analysis
Autor: Anil Vachani, Meijia Zhou, Sudip Ghosh, Shumin Zhang, Philippe Szapary, Dheeraj Gaurav, Iftekhar Kalsekar
Publikováno v: Journal of the American College of Radiology. 19:1121-1129
To provide recent population-based estimates of transthoracic needle biopsy (TTNB) complications and risk factors associated with these complications.This retrospective cohort analysis included adults from a nationally representative longitudinal ins
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::91869ee852b9b90096e32d3dcaa26fac
https://doi.org/10.1016/j.jacr.2022.04.010
Zobrazit plný text záznamu
3
The Effects of Ustekinumab on Health-related Quality of Life in Patients With Moderate to Severe Crohn’s Disease
Autor: Christopher Gasink, Long-Long Gao, Douglas Jacobstein, Brian G. Feagan, Stephan R. Targan, Bruce E. Sands, C. Han, William J. Sandborn, Philippe Szapary, Yinghua Lang
Publikováno v: Journal of Crohn's and Colitis. 12:883-895
Background and Aims We assessed the effect of ustekinumab on health-related quality of life [HRQOL] in adults with Crohn's disease [CD]. Methods Patients with moderately to severely active CD and inadequate response or intolerance to tumour necrosis
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ad5c0a87af22b73867a5a92028c629a4
https://doi.org/10.1093/ecco-jcc/jjy055
Zobrazit plný text záznamu
4
Pharmacokinetics and Exposure Response Relationships of Ustekinumab in Patients With Crohn's Disease
Autor: Stephen B. Hanauer, Omoniyi J. Adedokun, Christopher Gasink, Subrata Ghosh, Jewel Johanns, Zhenhua Xu, Philippe Szapary, Hugh M. Davis, William J. Sandborn, Long Long Gao, Douglas Jacobstein, Brian G. Feagan
Publikováno v: Gastroenterology. 154:1660-1671
Background & Aims Ustekinumab is a monoclonal antibody that binds with high affinity to the p40 subunit of human interleukin 12 (IL12 and IL23) that has been approved for treatment of patients with moderate to severe Crohn's disease (CD). However, th
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3026c4a872adf505fd73e248aede45e0
https://doi.org/10.1053/j.gastro.2018.01.043
Zobrazit plný text záznamu
8
First-in-human study to assess guselkumab (anti-IL-23 mAb) pharmacokinetics/safety in healthy subjects and patients with moderate-to-severe psoriasis
Autor: Honghui Zhou, Allen Schantz, Stanley J. Marciniak, Hugh M. Davis, Esther Bouman-Thio, Tong-Yuan Yang, Cesar Calderon, Zhenhua Xu, Philippe Szapary, Yanli Zhuang
Publikováno v: European Journal of Clinical Pharmacology. 72:1303-1310
The purpose of this study is to evaluate the pharmacokinetics, immunogenicity, safety, and tolerability of guselkumab, a human monoclonal antibody with high affinity and specificity for binding to interleukin-23.In this first-in-human, phase 1, rando
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5f626354c3444c1959db220fcb99c739
https://doi.org/10.1007/s00228-016-2110-5
Zobrazit plný text záznamu
9
Ustekinumab Pharmacokinetics and Exposure Response in a Phase 3 Randomized Trial of Patients With Ulcerative Colitis
Autor: Silvio Danese, Colleen Marano, Rupert W. Leong, Maria T. Abreu, Philippe Szapary, Omoniyi J. Adedokun, Hongyan Zhang, Gert Van Assche, Jewel Johanns, Christopher D. O'Brien, Zhenhua Xu, William J. Sandborn, Tadakazu Hisamatsu, Bruce E. Sands
Publikováno v: Clinical Gastroenterology and Hepatology. 18:2244-2255.e9
BACKGROUND & AIMS: The efficacy of antibody-based therapeutics depends on their pharmacokinetics. The pharmacokinetic and exposure response profiles of ustekinumab, a monoclonal antibody against interleukin 12/interleukin 23, are known in patients wi
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9ccef513eb5ea0b212f37403a198f648
https://doi.org/10.1016/j.cgh.2019.11.059
Zobrazit plný text záznamu
10
Peficitinib, an Oral Janus Kinase Inhibitor, in Moderate-to-severe Ulcerative Colitis: Results From a Randomised, Phase 2 Study
Autor: Gary R. Lichtenstein, Richard Strauss, Colleen Marano, Jewel Johanns, Kirk Bertelsen, Brian G. Feagan, Christopher D. O'Brien, Philippe Szapary, Zijiang Yang, Julián Panés, Bruce E. Sands, Hongyan Zhang, William J. Sandborn, Severine Vermeire
Publikováno v: Journal of Crohn'scolitis. 12(10)
Background and aims Janus kinase [JAK] inhibitors have shown efficacy in ulcerative colitis [UC]. We studied the dose-response, efficacy, and safety of peficitinib, an oral JAK inhibitor, in patients with moderate-to-severe UC. Methods In this Phase
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a056f1d955f83e967842a1245e12be7c
https://pubmed.ncbi.nlm.nih.gov/29917064
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje